Dronabinol buccal - IntelGenx

Drug Profile

Dronabinol buccal - IntelGenx

Alternative Names: CAT 310; Dronabinol AdVersa® Mucoadhesive tablet; Dronabinol XL; INT 0010; INT 0010/2006; INT-0028; INT0028/2011; Relivar

Latest Information Update: 10 Apr 2017

Price : $50

At a glance

  • Originator Cannasat Therapeutics
  • Developer IntelGenx Corp.
  • Class Antiemetics; Appetite stimulants; Cannabinoids; Muscle relaxants; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Neuropathic pain
  • Discontinued Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 03 Apr 2017 IntelGenx signs a definitive agreement with Tetra Bio-Pharma for development and commercialisation of dronabinol buccal
  • 09 Feb 2017 IntelGenx and Tetra Bio-Pharma sign binding term sheet for the development and commercialisation of dronabinol buccal
  • 21 Oct 2016 Cynapsus Therapeutics has been acquired by Sunovion Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top